Vax2Muc Project Website Now Live!

Visit www.vax2muc.eu/ to explore the comprehensive resources and information about our initiative to develop novel vaccine technologies targeting GI/AMR mucosal pathogens. The website serves as a central hub for the EU funded project, providing a platform to share updates, resources.

Why Vax2Muc Matters: The constant rise in antimicrobial resistance (AMR) has a major impact on global public health, and novel strategies to prevent and treat bacterial infections are urgently required. The development of effective vaccines as an alternative to treatment with antibiotics will be an attractive cost-effective alternative - and a major step forward for patients.

For many bacterial infections effective vaccines simply do not exist. This is especially true for infections that occur on mucosal sites, such as in the gastrointestinal tract. At the same time, such infections are incredibly common: Half of the world´s population is affected by Helicobacter pylori (H. pylori), a pathogen that resides in the stomach and causes chronic bacterial infection with a high risk of progression to gastric cancer. The standard-of-care for H. pylori infection is still an antibiotic therapy, which means the rise in AMR that we currently see severely hampers effective treatment. Therefore, the WHO recently declared H. pylori a priority neglected AMR target pathogen and emphasized that rapid intervention is urgently required.

This is where the Vax2Muc team comes in. Bringing together experts from various fields, and equipped with EU funding, the team sets out to explore new ways in combatting gastrointestinal mucosal pathogens by developing a prophylactic vaccine candidate and gaining knowledge about novel vaccine technologies applicable for various other GI/AMR mucosal pathogens.